Eli Lilly said its drugs showed no signs of live injury in the trial. This is welcome news for researchers after Pfizer ...

The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.

Continue » The leader in diabetes and obesity Despite Lilly's huge success in treating diabetes and obesity, it's not the ...

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, ...

Eli Lilly’s orforglipron pill, licensed from Chugai Pharmaceutical, could reshape the booming weight-loss drug market, early ...

Eli Lilly's new oral weight loss pill, orforglipron, shows promise in Phase 3 trials, offering a convenient alternative to ...

If approved for wide release, the pill, orforglipron, could shake up the booming GLP-1 market by offering an option that's easier to make and store than the injections that are currently available.

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Eli Lilly stocks displayed a major rise after the announcement of a new oral weight-loss drug that has put pressure on its ...

Eli Lilly & Co. shares surged after its experimental pill helped patients shed weight and control blood sugar about as well ...

The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...